Page 49 - 2019_08-Haematologica-web

MRD in AML
61. Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long- term remission patients with t(8;21) acute myelogenous leukemia. Blood. 1996;87(11): 4789-4796.
62. Diverio D, Rossi V, Avvisati G, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood. 1998;92(3): 784-789.
63. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875- 1891.
64. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111-121.
65. Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelo- cytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129(10):1275-1283.
66. Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
67. Boddu P, Gurguis C, Sanford D, et al. Response kinetics and factors predicting sur- vival in core-binding factor leukemia. Leukemia. 2018;32(12):2698-2701.
68. Leroy H, de Botton S, Grardel-Duflos N, et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia. 2005;19(3):367-372.
69. Weisser M, Haferlach C, Hiddemann W, Schnittger S. The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk fac- tors. Leukemia. 2007;21(6):1177-1182.
70. Zhu HH, Zhang XH, Qin YZ, et al. MRD- directed risk stratification treatment may
improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121 (20):4056-4062.
71. Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucle- ophosmin (NPM1): is it a distinct entity? Blood. 2011;117(4):1109-1120.
72. Jain P, Kantarjian H, Patel K, et al. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014;55(6):1337-1344.
73. Kayser S, Benner A, Thiede C, et al. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Blood Cancer J. 2016;6(7):e449.
74. Maurillo L, Buccisano F, Spagnoli A, et al. Monitoring of minimal residual disease in adult acute myeloid leukemia using periph- eral blood as an alternative source to bone marrow. Haematologica. 2007;92(5):605- 611.
75. Zeijlemaker W, Kelder A, Oussoren- Brockhoff YJ, et al. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophe- notypic biomarker for impending relapse in acute myeloid leukemia. Leukemia. 2016;30(3):708-715.
76. Umetani N, Giuliano AE, Hiramatsu SH, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 2006;24(26):4270-4276.
77. Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detec- tion. Nat Rev Clin Oncol. 2018;15(9):577- 586.
78. Assi RE, Albitar M, Ma W, et al. Comparison of somatic mutations profiles from next- generation sequencing (NGS) of cell-free DNA (cfDNA) versus bone marrow (BM) in acute myeloid leukemia (AML). J Clin Oncol. 2018;36(15_suppl):7051-7051.
79. Nakamura S, Yokoyama K, Shimizu E, et al. Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in acute myeloid
leukemia and myelodysplastic syndrome.
Blood. 2018;132(Suppl 1):247.
80. Gokbuget N, Dombret H, Bonifacio M, et al.
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lym- phoblastic leukemia. Blood. 2018;131(14): 1522-1531.
81. Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic char- acterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood. 2010;116(13):2295-2303.
82. Sockel K, Wermke M, Radke J, et al. Minimal residual disease-directed preemp- tive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Haematologica. 2011;96(10):1568-1570.
83. Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allo- geneic HSCT: results of the RELAZA trial. Leukemia. 2012;26(3):381-389.
84. Platzbecker U, Middeke JM, Sockel K, et al. Measurable residual disease-guided treat- ment with azacitidine to prevent haemato- logical relapse in patients with myelodys- plastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multi- centre, phase 2 trial. Lancet Oncol. 2018;19(12):1668-1679.
85. Ragon BK, Daver N, Garcia-Manero G, et al. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2017;92(9):845-850.
86. Boumber Y, Kantarjian H, Jorgensen J, et al. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012;26(11): 2428-2431.
87. Blum W, Sanford BL, Klisovic R, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503). Leukemia. 2017;31(1):34-39.
haematologica | 2019; 104(8)
1541